SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com -- Qiagen (NYSE:QGEN), a leading global provider of molecular diagnostics and sample preparation technologies, has increased its full-year 2025 adjusted diluted earnings per share (EPS) outlook.
The company now anticipates an EPS of approximately $2.35, a rise from its previous projection of around $2.28.
In addition to this, Qiagen has reported preliminary results for the first quarter of the year. The company’s adjusted EPS is estimated to be at least 55 cents, surpassing the Bloomberg Consensus estimate of 49 cents.
Moreover, Qiagen’s net sales at constant exchange rates for the first quarter stand at $483 million.
The revision in the 2025 EPS outlook comes in light of Qiagen’s strong sales growth in the first quarter and current business trends. These include anticipated challenges from the recently introduced U.S. import tariffs and a tax environment that has been better than expected.
Additionally, Qiagen is maintaining its objective to enhance the adjusted operating income margin to more than 30% for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.